Miller DM - Search Results

1

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.

Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, Klarer AC, Redman R, Miller DM, Trent JO, Telang S, Chesney J. Clem BF, et al. Among authors: miller dm. Mol Cancer Ther. 2013 Aug;12(8):1461-70. doi: 10.1158/1535-7163.MCT-13-0097. Epub 2013 May 14. Mol Cancer Ther. 2013. PMID: 23674815 Free PMC article.

2

Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.

Natarajan N, Telang S, Miller D, Chesney J. Natarajan N, et al. Drugs. 2011 Jul 9;71(10):1233-50. doi: 10.2165/11591380-000000000-00000. Drugs. 2011. PMID: 21770473 Review.

3

Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Bates PJ, et al. Among authors: miller dm. Exp Mol Pathol. 2009 Jun;86(3):151-64. doi: 10.1016/j.yexmp.2009.01.004. Epub 2009 Jan 20. Exp Mol Pathol. 2009. PMID: 19454272 Free PMC article. Review.

4

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.

Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J. Telang S, et al. Among authors: miller dm. BMC Cancer. 2011 Dec 13;11:515. doi: 10.1186/1471-2407-11-515. BMC Cancer. 2011. PMID: 22165955 Free PMC article. Clinical Trial.

5

Transient T cell depletion causes regression of melanoma metastases.

Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J. Rasku MA, et al. Among authors: miller dm. J Transl Med. 2008 Mar 11;6:12. doi: 10.1186/1479-5876-6-12. J Transl Med. 2008. PMID: 18334033 Free PMC article. Clinical Trial.

6

Digitalis, a targeted therapy for cancer?

Khan MI, Chesney JA, Laber DA, Miller DM. Khan MI, et al. Among authors: miller dm. Am J Med Sci. 2009 May;337(5):355-9. doi: 10.1097/MAJ.0b013e3181942f57. Am J Med Sci. 2009. PMID: 19440057 Review.

7

Antiproliferative activity of G-rich oligonucleotides correlates with protein binding.

Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM. Bates PJ, et al. Among authors: miller dm. J Biol Chem. 1999 Sep 10;274(37):26369-77. doi: 10.1074/jbc.274.37.26369. J Biol Chem. 1999. PMID: 10473594 Free article.

8

Melanoma of unknown primary: favorable survival persists in the immunotherapy era.

Maharaj S, Jain N, Al Bawaliz A, Miller D, Chesney J. Maharaj S, et al. Int J Dermatol. 2023 Apr;62(4):e236-e238. doi: 10.1111/ijd.16419. Epub 2022 Aug 28. Int J Dermatol. 2023. PMID: 36030543 No abstract available.

9

Obtaining routine blood cultures during interleukin-2-containing therapy is unnecessary.

Jaglal MV, Laber DA, Arnold FW, Miller DM, Chesney JA, Kloecker GH. Jaglal MV, et al. Among authors: miller dm. Am J Clin Oncol. 2009 Aug;32(4):429-31. doi: 10.1097/COC.0b013e31819142c7. Am J Clin Oncol. 2009. PMID: 19451801

10

5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma.

Gill A, Gosain R, Gragg H, Bycroft R, Rai SN, Pan J, Chesney JA, Miller DM. Gill A, et al. Among authors: miller dm. Am J Med Sci. 2019 Jan;357(1):43-48. doi: 10.1016/j.amjms.2018.10.009. Epub 2018 Oct 25. Am J Med Sci. 2019. PMID: 30611319

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

736 results

Search Page

Filters